EUVIMEDEUVIMED entdecken
Crossref

Innovative medicines by supercritical fluid particle design: Four decades of progress

Yongda Sun

Innovative Medicines & Omics · 22.05.2026 · 3 (4) · 025440059

DOI: 10.36922/imo025440059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Medicines & Omics, online erschienen am 22.05.2026. Verfasst von Yongda Sun.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Innovative medicines are increasingly relying on advanced technologies spanning discovery, formulation, manufacturing, and regulation. Supercritical fluid particle design (SCF PD) is an emerging pharmaceutical platform that has evolved from laboratory research to industrial application over the past four decades. Transforming active pharmaceutical ingredients into innovative medicines requires coordinated optimization in aspects such as particle size, crystal form and morphology, solubility, absorption, bioactivity, functional structure, stability, and biocompatibility. In achieving this goal, SCF PD can not only produce pure drug particles but also manufacture composite particles with functional structures, such as hybrid nanoparticles, co-crystals, porous particles, and coated particles, which can be used in controlled-release, taste-masking, carrier-free inhalation, and other drug delivery system formulations. With the advancement of technology, equipment, and processes, innovative medicines developed through SCF PD have entered clinical trials and Good Manufacturing Practices production, such as StaniTab® sirolimus nanocrystal direct-compression tablets, Dasynoc® dasatinib hybrid nanodispersion tablets, Nano-enzalutamide 160 mg single-dose amorphous nanopowder tablets, and Zindol® ginger extract capsules. This narrative review focuses on the advances in innovative medicines for poorly soluble drugs, anticancer drugs, and inhalation drugs, emphasizing the simplification of complex manufacturing processes, dose reduction, improvement of medicine quality, enhancement of therapeutic efficacy, and increased patient adherence, providing important guidance for better utilization of SCF PD technology in the production of innovative medicines.

Zitieren

APA

Sun, Y. (2026). Innovative medicines by supercritical fluid particle design: Four decades of progress. Innovative Medicines & Omics, 3(4), 025440059. https://doi.org/10.36922/imo025440059

Vancouver

Sun Y. Innovative medicines by supercritical fluid particle design: Four decades of progress. Innovative Medicines & Omics. 2026;3(4):025440059. doi:10.36922/imo025440059

BibTeX
@article{Sun2026,
  author = {Sun, Yongda},
  title = {Innovative medicines by supercritical fluid particle design: Four decades of progress},
  journal = {Innovative Medicines & Omics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {025440059},
  doi = {10.36922/imo025440059}
}
Kostenlos starten →